Skip to main content
. Author manuscript; available in PMC: 2021 Nov 16.
Published in final edited form as: Oncogene. 2021 Sep 23;40(44):6235–6247. doi: 10.1038/s41388-021-02017-8

Fig. 1. ISG15 expression is associated with poor outcome in breast cancer patients with lymph-node metastasis.

Fig. 1

(A) Kaplan–Meier plot of disease-free survival of breast cancer patients (n=2643) separated into two groups with high (blue) or low (red) mRNA expression levels of ISG15. (B) Kaplan-Meier plot of free disease survival of patients from A that are negative for tumour cells in lymph nodes (n=740). (C) Kaplan-Meier plot of free disease survival of patients from A positive for tumour presence in lymph nodes (n=1178). (D) Kaplan-Meier plot of disease-free survival association with mRNA levels of UBE2L6, separated into two groups with high (blue) or low (red) levels, in lymph node positive patients (n=744) or lymph node negative patients (n=350). As in (D) analysis of mRNA levels in lymph node positive and negative of the interferon coding genes IFNA1 (n=600) (E) and IFNB1 (n=744) (F). (G) WB analysis of the indicated representative clones to confirm the knockout, cells were treated for 48h with either vehicle or IFNb1a 250pM to boost the protein levels of the different ISGylation-related proteins.